{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:35:55Z","timestamp":1772858155650,"version":"3.50.1"},"reference-count":116,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.1080\/13543776.2021.1886275","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T10:35:08Z","timestamp":1613039708000},"page":"609-623","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)"],"prefix":"10.1080","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-5624","authenticated-orcid":false,"given":"Uday Kiran","family":"Velagapudi","sequence":"first","affiliation":[{"name":"Pace Analytical Life Sciences, LLC, Suite 102, 19 Presidential Way, Woburn, MA, 01801, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-3803","authenticated-orcid":false,"given":"Bhargav A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, The University of Notre Dame, 329 McCourtney Hall, Notre Dame, IN 46556, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuwei","family":"Shao","sequence":"additional","affiliation":[{"name":"cFrontage Laboratories, Inc, 75 East Uwchlan Ave, Suite 100, Exton, PA, 19341, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1799-9730","authenticated-orcid":false,"given":"Sanjai Kumar","family":"Pathak","sequence":"additional","affiliation":[{"name":"dChemistry and Biochemistry Department, Queens College of the City University of New York, 65-30 Kissena Blvd., Flushing, NY, 11367, USA;"},{"name":"eChemistry Doctoral Program, Biochemistry Doctoral Program, The Graduate Center of the City University of New York, 365 5th Ave, New York, NY, 10016, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5791-5939","authenticated-orcid":false,"given":"Dana V.","family":"Ferraris","sequence":"additional","affiliation":[{"name":"fDepartment of Chemistry, McDaniel College, 2 College Hill, Westminster, MD, 21157, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-6505","authenticated-orcid":false,"given":"Tanaji T.","family":"Talele","sequence":"additional","affiliation":[{"name":"gDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John\u2019s University, Queens, NY, 11439, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00055"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1101\/gad.291518.116"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1259413"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2013.768615"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3748"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5426"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1021\/jm100012m"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.25.17860"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1021\/cr900047g"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"issue":"80","key":"cit0012","first-page":"368","volume":"368","author":"Zandarashvili L","year":"2020","journal-title":"Science"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1021\/jm8001263"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1021\/jm901188v"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0552"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01498"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112570"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12320"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.2174\/1381612820666140630101525"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1888929"},{"key":"cit0022","first-page":"1","author":"Verma A","year":"2020","journal-title":"Med Chem Res"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.12.006"},{"key":"cit0024","unstructured":"Vasbinder M. RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways."},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.09.011"},{"key":"cit0026","first-page":"167","volume":"384","author":"Kaufmann M","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00445"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1021\/cb4002014"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.04.056"},{"key":"cit0030","doi-asserted-by":"crossref","unstructured":"Yang C. S, Jividen K, Spencer A, et al. Ubiquitin Modification by the E3 Ligase\/ADP-Ribosyltransferase Dtx3L\/Parp9. Mol Cell. 2017; 66(4): 503\u2013516.","DOI":"10.1016\/j.molcel.2017.04.028"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.8b00569"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00680"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01709"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200800010"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00050"},{"issue":"5","key":"cit0036","volume":"8","author":"Hu H","year":"2020","journal-title":"PeerJ"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.05.016"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00002"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0271-9"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1021\/jm5006463"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.10.010"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00622"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2017.05.058"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2008.05.044"},{"issue":"15","key":"cit0045","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1158\/1538-7445.AM2015-1653","volume":"75","author":"Tang Z","year":"2015","journal-title":"Cancer Res"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.2505"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5846"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4060"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13749"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2121"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00990"},{"key":"cit0052","unstructured":"Southeast University, Nanjing. Derivative based on PARP inhibitor niraparib and a preparation method and use thereof. CN110343088 A (2019)."},{"key":"cit0053","unstructured":"Selection Bioscience, LLC. Poly(ADP-Ribose) Polymerase inhibitor, preparation method and use. WO2018228474 A1 (2018)."},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2853"},{"key":"cit0055","unstructured":"Shanghai Institute of Materia Medica. 2-substituted Benzimidazole-4-Carboxamide compound and preparation method and use thereof. WO2016206651 A1 (2016)."},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.01.018"},{"key":"cit0057","unstructured":"Shenzhen Kunjian Innovation Medicine Research Institute. Fluorine-containing substituted benzimidazole derivatives and application thereof. CN108997320 A (2018)."},{"key":"cit0058","unstructured":"Guangzhou Dankang Medicine Biological Co., Ltd. Compound used as PARP inhibitor, and use thereof. CN107964012 A (2016)."},{"key":"cit0059","unstructured":"Sichuan University. Phthalimide derivative as well as preparation method and application thereof. CN110028439 A (2019)."},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.9.2141"},{"key":"cit0061","unstructured":"Guangzhou Wellhealth Bio-Pharmaceutical Co., Ltd. Polycyclic compound having PARP inhibition activity, and uses thereof. WO2018192445 A1 (2018)."},{"key":"cit0062","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Phthalazine Ketone derivative, and preparation method and use thereof. WO 2017071636 A1; WO2017101796 A1 (2017)."},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0433"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0234"},{"key":"cit0065","unstructured":"Shanghai Weicen Pharmaceutical Technology Co., Ltd. PARP inhibitor, medicine composition, preparation method and application thereof. CN108164468 A (2018)."},{"key":"cit0066","unstructured":"China Pharmaceutical University. Benzo[4,5]Imidazole[1,2-a]Pyrazine Ketone derivatives as well as preparation method and application thereof. CN109748923 A (2019)."},{"key":"cit0067","unstructured":"Shanghai Huilun Life Sciences and Technology Co., Ltd. Heterocyclic-Imidazole compounds, pharmaceutical composition thereof, preparation method therefor and use thereof. WO2016165655 A1 (2016)."},{"key":"cit0068","unstructured":"China Pharmaceutical University. PARP (Poly (ADP-Ribose) Polymerase)-1 and Tankyrase1\/2 multi-target inhibitors as well as preparation method and application thereof. CN108358850 A (2018)."},{"key":"cit0069","unstructured":"Beijing Collab Pharma Co., Ltd. Quinazolinone PARP-1 inhibitors, medicinal composition containing inhibitors, and antitumor use of inhibitors. CN105461697 A (2016)."},{"key":"cit0070","unstructured":"Shanghai Xunhe Pharmaceutical Technology Co., Ltd. Substituted 2,4-(1H,3H) Pyrimidinedione derivative adopted as PARP inhibitor, and applications thereof. CN107629071 B (2018)."},{"key":"cit0071","unstructured":"Institute of Materia Medica, Chinese Academy of Medical Sciences. Piperazinone-containing quinazolinone PARP-1\/2 inhibitor, and preparation method, medicine composition and purpose thereof. CN107098886 B (2017)."},{"key":"cit0072","unstructured":"Institute of Materia Medica. 3-Amino Nafoxidine-containing quinazoline ketone PARP (Poly Adenosine Diphosphate Ribose Polymerase)-1\/2 inhibitor as well as preparation method, medicinal composition and application thereof. CN108727343 A (2018)."},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1039\/C8OB00286J"},{"key":"cit0074","unstructured":"Hua J. Substituted 2,4-(1H,3H)- Pyrimidinedione as PARP inhibitor and use thereof. WO2017177838 A1 (2017)."},{"key":"cit0075","unstructured":"Shenzhen TargetRx, Inc. Substituted Phthalazone and Pharmaceutical composition thereof. WO2017181918 A1 (2017)."},{"key":"cit0076","unstructured":"Lupin Ltd. Isoquinoline derivatives as PARP Inhibitors. WO2016012956 A1 (2016)."},{"key":"cit0077","unstructured":"Lupin Ltd. Isoquinoline derivatives as PARP Inhibitors. WO2017013593 A1 (2017)."},{"key":"cit0078","unstructured":"Shanghai Xunhe Pharmaceutical Technology Co., Ltd. Substituted 1,3,4,5-Tetrahydro-6H-Pyrrolo[4,3,2-EF] [2] Benazepine-6-Ketone derivatives. CN107286166 B (2016)."},{"key":"cit0079","unstructured":"Shanghai Zhaoyu Medicine Technology Co., Ltd. Pyrazole quinazolinone derivative serving as PARP (Poly ADP-Ribose Polymerase) inhibitor and application of pyrazole quinazolinone derivative serving as PARP inhibitor. CN109265463 B (2019)."},{"key":"cit0080","unstructured":"Guangzhou Wellhealth Bio-Pharmaceutical Co., Ltd. PARP inhibitor, pharmaceutical composition, preparation method and use thereof. WO2018205938 A1 (2018)."},{"key":"cit0081","unstructured":"Suzhou Kangrun Pharmaceuticals, Inc. Derivative of Nitrogen-Doped Phenalene-3-Ketone, preparation method therefor and application of derivative used as PARP inhibitor. WO2016188307 A1 (2016)."},{"key":"cit0082","unstructured":"Suzhou Kangrun Pharmaceuticals, Inc. Azaphenalene-3-one derivative, preparation method therefor and application thereof. WO2018177444 A2 (2018)."},{"key":"cit0083","unstructured":"Guangzhou Dankang Pharmaceutical Biological Co., Ltd. Novel fused ring compound used as PARP inhibitor, and preparation method and application thereof. CN107573341 B (2018)."},{"key":"cit0084","unstructured":"BeiGene, Ltd. Fused tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as PARP inhibitors. US20190016731 B2 (2019)."},{"key":"cit0085","unstructured":"University of Ryukyus. PARP inhibitor containing syzygium samarangense extract. JP2017218382 B2 (2017)."},{"key":"cit0086","unstructured":"Fox Chase Cancer Center. Poly (ADP-Ribose) Polymerase 1 inhibitors structurally unrelated to NAD. WO2016054237 A2 (2016)."},{"key":"cit0087","author":"Makhov P","year":"2020","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"cit0088","unstructured":"Sichuan University. Dihydro Dibenzooxepin derivative as well as composition and application thereof. CN106117176 B (2016)."},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01946"},{"key":"cit0090","unstructured":"Shenzen Kivita Innovative Drug Institute. Phthalazone hydroxamic acid derivative, preparation therefor and application thereof. WO2018177126 A1 (2018)."},{"key":"cit0091","unstructured":"SignalRx Pharmaceuticals, Inc. Single molecule compounds providing multi-target inhibition of PARP and other proteins and methods of use thereof. WO2018236971 A1 (2018)."},{"key":"cit0092","unstructured":"The Regents Of The University of California. Anti-cancer compounds. WO2016187620 A2 (2016)."},{"key":"cit0093","unstructured":"Shanghai Biobond Pharmaceutical Co., Ltd. Phthalazone derivative prodrug or pharmaceutically acceptable salt thereof, and pharmaceutical composition and application thereof. WO2019144875 A1 (2019)."},{"key":"cit0094","unstructured":"Oregon Health and Sciences University. PARP inhibitors for treating cancer and asthma. WO2020046753 A1 (2020)."},{"key":"cit0095","unstructured":"Oregon Health and Science University. Inhibitors of PARPs that catalyze mono-ADP-ribosylation. US20190062302 A1 (2018)."},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.8b00429"},{"key":"cit0097","first-page":"153","volume":"384","author":"Pinto AF","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"cit0098","unstructured":"Ribon Therapeutics, Inc. Quinazolinones as PARP14 inhibitors. WO2019126443 (2019)."},{"key":"cit0099","unstructured":"Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors. US20200123134 A1 (2020)."},{"issue":"11","key":"cit0100","first-page":"496","volume":"34","author":"Chen DH","year":"2015","journal-title":"Chin J Cancer"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00028"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0544"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1038\/nature18325"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.05.008"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806092105"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.4161\/cc.22026"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09312-9"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00390-7"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.09.021"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.11.031"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00821"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1039\/C8CC07813K"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2020.1804382"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M701021200"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601301"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604252103"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2021.1886275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T06:27:13Z","timestamp":1665988033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2021.1886275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":116,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,3]]}},"alternative-id":["10.1080\/13543776.2021.1886275"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2021.1886275","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}